Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau antibody designed to slow or prevent the progression of AD. [WATCH TIME: 5 minutes]

AAIC 2025 Preclinical Results of Anti-Tau Antibody MK-2214 in Alzheimer Disease: Jonathan Sugam, PhD

Articles

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the use of lithium to treat Alzheimer disease.

NeurologyLive® Brain Games: August 17, 2025

At the 2025 ATMRD Congress, Anissa Mitchell, LCSW, chief program officer at PMD Alliance, discussed immersive, patient-focused sessions aimed at improving clinicians’ empathy, communication, and understanding of Parkinson disease and related disorders.

Building Empathy Through Patient-Centered Simulations: Perspectives From 2025 ATMRD Congress 

Electronic Health Record Study Finds No Significant Cardiovascular Risk With Triptan Use for Migraine

, has been with the team since September 2022. Follow her on Twitter 

Medical director of CNS Clinical Development at AskBio.

The medical director of CNS Clinical Development at AskBio discussed long-term data presented at ATMRD from the company’s phase 1b assessing the investigational gene therapy AB-1005 in Parkinson disease. [WATCH TIME: 6 minutes]  

Overviewing 36-Month, Phase 1b Data Testing Gene Therapy AB-1005 in Parkinson Disease: Nisha Chhabria MD, FAAN

At AAIC 2025, Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, discussed the association between long sleep duration, specific sleep phenotypes, and progressive cognitive decline in Hispanic populations.

Measuring Sleep Duration and Identifying Phenotypes Linked to Cognitive Decline in Hispanic Populations

The clinical assistant professor in movement disorders at Jefferson Health outlined a patient-centered, lifestyle-first approach to managing Parkinson nonmotor symptoms. [WATCH TIME: 4 minutes]

Addressing Constipation, Sleep, and Fatigue in Parkinson Disease Care: Alexa Dessy, MD

Dementia & Alzheimer's disease condition center is a resource for news on the diagnosis, treatment, & management of dementia & Alzheimer's. | NeurologyLive.


Dementia & Alzheimer Disease | Clinical Neurology News | NeurologyLive

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAIC 2025

CMSC 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1.125rem

Clinical

 dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.

 to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

In this episode, "Overviewing Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer Care," John Sims, MD, head of medical development for donanemab at Eli Lilly and Company, joins NeurologyLive to discuss the recently updated label for donanemab (Kisulna), an anti-amyloid Alzheimer disease (AD) therapy. Sims breaks down the key safety data from the TRAILBLAZER-ALZ-6 study (NCT05738486) that led to a newly approved titration-based dosing regimen aimed at minimizing ARIA risk. He outlines considerations for clinicians treating patients with early-stage AD, including genotype-based stratification, ARIA severity patterns, and implications for prescribing and patient counseling. Furthermore, Sims also shares takeaways about donanemab’s clinical impact and how the results may shape the future of anti-amyloid therapy development and AD care.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies

FDA Shuts Down Sarepta's Distribution of Gene Therapy Elevidys Following Patient Deaths

AD109 Meets End Points in Phase 3 LunAIRo Trial, Eyeing FDA Submission for Obstructive Sleep Apnea

 – Overview of the new donanemab dosing regimen and its goal to reduce ARIA risk

 – Rationale behind the four different dosing strategies tested in Trailblazer-ALZ-6

 – What clinicians should know about patient risk and genotype testing

 – Clinical implications of the updated label, including risk-benefit conversations

 – Surprising results from the trial, particularly for APOE4 homozygous patients

 to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with John Sims, MD. [LISTEN TIME: 17 minutes]

Episode 146: Overviewing Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer Care

In this episode, "Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress," Elizabeth Head, PhD, professor in the department of Pathology and Laboratory Medicine at the University of California, Irvine, discussed the evolving intersection of Down syndrome and Alzheimer disease using updates from the Alzheimer Biomarker Consortium – Down Syndrome (ABC-DS). She detailed how outcome assessments have been refined to meet the unique cognitive profiles of individuals with Down syndrome and shared the progress in launching clinical trials that now include this historically excluded population. Head also addressed the challenges in distinguishing developmental delay from early dementia symptoms, the potential role of anti-amyloid therapies, and how non-pharmacological interventions like sleep apnea treatment may contribute to cognitive preservation. She emphasized the importance of equitable research participation, clinician education, and understanding patient priorities—like independence and respect—when supporting individuals with Down syndrome and their families.

GENERATION HD2 Trial of Huntington Agent Tominersen Amended to Include Only Higher Dose

FDA Grants Authorization to Epiminder’s Implantable Continuous EEG Monitor for Epilepsy Treatment

FDA Approves FcRn Blocker Nipocalimab for Broad Forms of Generalized Myasthenia Gravis

 – Overview of the ABC-DS initiative and the growing inclusion of Down syndrome in Alzheimer research

– Current state of clinical trials and progress in therapeutic development for this population

 – Evolution of outcome assessments tailored for individuals with Down syndrome

 – Challenges in distinguishing Down syndrome traits from signs of early dementia

 – Clinician educations needs and improving access to specialized care

 – Eligibility and considerations for anti-amyloid therapies in Down syndrome

 – Research gaps, co-occurring conditions, and the importance of reaching underserved populations

 – Top priorities from patients and families: independence, inclusion, and respect in care settings

AD/PD International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Elizabeth Head, PhD. [LISTEN TIME: 20 minutes]

Episode 140: Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress

In this episode, "Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test," Russ Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the company's SAAmplify-aSYN biomarker test, a first-in-class qualitative laboratory developed test and the only seed amplification assay available to aid in the diagnosis of synucleinopathies such as Parkinson disease (PD) and multiple system atrophy (MSA). Lebovitz provided insight on the new technology and its remarkable accuracy in identifying underling a-synuclein pathology using fluorescence changes. He gave a complete overview of the notable study published in 

 that further tested and validated the assay among a heterogenous group of synucleinopathies. Furthermore, he provided clinical context on the feasibility of the assay, the potential for clinical use, and the continued validation needed. 

Axsome to Submit NDA for AXS-05 in Alzheimer Agitation Following Positive Phase 3 Trials

FDA Clears IND for Trial Assessing Gene Therapy SGT-212 in Friedreich Ataxia

FDA Grants Fast Track Designation to Anti-Tau Therapy Posdinemab

 – Overviewing mechanistic function of SAAmplify-aSYN biomarker test, its purpose, and how it came about

 – Results from the published study; ways the fluorescence-based amplification method could distinguish MSA from PD and Lewy body dementia

 – Therapeutic feasibility of the assay in clinical settings and the next steps in validation

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Russell Lebovitz, MD, PhD. [LISTEN TIME: 22 minutes]

Episode 132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test

Episode 131, "Neurology Unwrapped: 2024's Most Intriguing Conversations" compiles some of the most compelling conversations from 

 podcast episodes throughout 2024. These discussions spotlight groundbreaking research and advancements in neurology that are propelling the field forward. The 

 team also explored the impact of several newly FDA-approved therapies, offering clinicians valuable insights into what these treatments mean for patient care and their practical use in the clinic. Featured in this week’s episode, in order of appearance, are:


, staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, gives an overview on the new 2024 McDonald criteria to diagnose multiple sclerosis (MS), which was presented at the 

40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, on the changing and exciting advances in Alzheimer disease therapeutics, as well as the discontinuation of aducanumab, the first approved antiamyloid therapy.

Lessons Learned in Alzheimer Drug Development

, vice chair of the American Academy of Sleep Medicine's Practice Guidelines Task Force, discusses the newly revised guidelines for restless legs syndrome, including the latest updates in literature and changes to clinical care.

Implications of the 2024 AASM Guidelines for Restless Legs Syndrome

, a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease.

Utilizing the Syn-One Test to Diagnose Parkinson Disease

, an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke at the 2024 American Epilepsy Society Annual Meeting on cell therapy approaches for epilepsy, the challenges the clinical community faces, and the outlook for the future.

The Promise Behind Cell Therapy Approaches in Epilepsy

, a senior scientist at Sunnybrook Research Institute, gives insight on educating the next generation of neuromuscular and electrodiagnostic (EDX) practitioners, and the major differences in how this generation of medical students learn relative to previous ones.

Adapting Neuromuscular and Electrodiagnostic Medicine Education for Modern Learners

 – Ontaneda on the incorporation of new biomarkers into the 2024 McDonald Criteria for multiple sclerosis.

 – Kremer on the lessons learned from drug development, including antiamyloid treatments, and initial reaction to the discontinuation of aducanumab for AD. 

 – Berkowski on the outlook of treating and preventing restless legs syndrome going forward using the newly updated American Academy of Sleep Medicine treatment guidelines. 

 – Husain-Wilson on the function of the Syn-One test for Parkinson disease, its applicability, and how it may distinguish patients with PD from other synucleinopathies.

 – Parker on the promise and thought process behind stem cell approaches for drug-resistant epilepsy, including the different types of cell methods being tested. 

 – Robinson on the distinct differences in learning styles based on generation, the importance of adaptive teaching, and the new approaches educators in neuromuscular and electrodiagnostic medicine can take. 

Mind Moments®, a podcast from NeurologyLive®, brings you a review of 2024, with insights from Daniel Ontaneda, MD, PhD; Ian Kremer; Andy Berkowski, MD, PhD; Sameea Husain-Wilson, DO; Jonathan Parker, MD, PhD; and Lawrence Robinson, MD. [LISTEN TIME: 25 minutes]

Neurology Unwrapped: 2024’s Most Intriguing Conversations

In this episode, "RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease," Sharon Cohen, MD, a behavioral neurologist, sat down to discuss positive data from an ongoing phase 1 study of mivelsiran (Alnylam Pharmaceuticals), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer disease (AD). Cohen, who also serves as the medical director of the Toronto Memory Program at the University of Toronto, discussed the potential of RNA therapeutics for treating AD, the unique mechanism of action of mivelsiran, and some of the early promising safety, efficacy, and pharmacokinetic data observed in the phase 1 trial. In addition, Cohen touched upon the idea of how RNA therapeutics could be used in combination with previously approved novel treatments and the benefits mivelsiran brings with no observed amyloid-related imaging abnormalities. Furthermore, the discussion covered some of the potential of this investigational agent, what to expect in the multi-dose part B of the study, and an additional phase 2 study in cerebral amyloid angiopathy.

FDA Clears Indapta Therapeutics’ IND for Cell Therapy IDP-023 in Progressive Multiple Sclerosis

Muscle-Targeting Therapy Apitegromab Effective in Spinal Muscular Atrophy Over 4 Year Period

FDA Approves Medtronic’s Deep Brain Stimulation Technology for Asleep Capabilities

 – Mechanism of action of mivelsiran and how it can be potentially beneficial in AD

– Growing knowledge of RNA therapeutics and their impact on neurologic conditions

– Phase 1 study data, including efficacy, safety, biomarker, and pharmacokinetic results

– How mivelsiran fits with other approved therapies for AD; future goals and directions of the drug

Alzheimer's Association International Conference (AAIC)

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sharon Cohen, MD. [LISTEN TIME: 20 minutes]

Episode 122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

This episode, "FDA Approves Donanemab for Early Symptomatic Alzheimer Disease," features an exclusive interview with Joel Salinas, MD, MBA, a behavioral neurologist at NYU Langone, to discuss the impacts of the approval. Salinas, who also serves as the chief medical officer at Isaac Health, gave insight on the considerations and caution with prescribing donanemab, including the importance of identifying whether patient's are a true candidate for treatment. In addition, he spoke on the education and awareness around these new novel treatments for AD, and some of the next steps in continuing momentum in the field going forward.

's coverage of donanemab's approval, head here: 

FDA Approves Eli Lilly's Donanemab for Early Symptomatic Alzheimer Disease

 – Positive downstream impacts of donanemab's approval

 – Considerations and caution with prescribing donanemab

 – Salinas on patient-clinician conversations about AD treatments

 – Closing remarks and continued progress in AD field

 podcast. Be sure to leave a rating and review for the show. Thanks for listening!

REFERENCES
1. Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease. News Release. Eli Lilly. Published July 2, 2024. Accessed July 9, 2024. https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joel Salinas, MD, MBA. [LISTEN TIME: 10 minutes]

Special Episode: FDA Approves Donanemab for Early Symptomatic Alzheimer Disease

Episode 116, "Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas" features a conversation with Katherine Peters, PhD, a neurologist and neurooncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided context on a new analysis from the phase 3 INDIGO trial, a study assessing vorasidenib in patients with mutant isocitrate dehydrogenase (mIDH) 1/2 diffuse gliomas. The conversation, which occurred at the 2024 AAN Annual Meeting, covered the covered the therapeutic potential of this agent and its impacts on quality of life, neurocognition, and seizure control. Peters, an expert in the field, provided insight on the mechanism of action of vorasidenib, the added value behind the exploratory analysis, and the next steps in research. Furthermore, she provided context on the patient sample observed and why these data may hold significant weight going forward.


Cross-Compatibility Issues With Autoinjectors Highlighted in New FDA Labeling Update of Glatiramer Acetate Injection

Biogen, Ionis Terminate BIIB105 Following Disappointing Phase 1/2 Results

Ataluren Remains on Market Following European Commission Decision to Spurn CHMP’s Negative Opinion

, a streaming channel from MJH Life Sciences

. Check out new content and shows every day, only at

 – Mechanism of action of vorasidenib, a mIDH 1/2 inhibitor

 – Overview of exploratory analysis results

 – Significance of new data, how it adds to previous primary and secondary outcomes

 – Next steps for the study and use of vorasidenib

 – Remaining unmet needs for patients with diffuse gliomas

American Academy of Neurology Annual Meeting (AAN)

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Katherine Peters, PhD. [LISTEN TIME: 13 minutes]

Episode 116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas

Episode 113, "Lessons Learned in Alzheimer Drug Development" features a conversation with Ian Kremer, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, who spoke on several relevant topics regarding Alzheimer care as new novel therapeutics emerge. He talked about the lessons learned from the recent discontinuation of aducanumab (Aduhelm; Biogen), and the potential and limitations lecanemab (Leqembi; Eisai) and donanemab (Eli Lilly) may bring. Additionally, he provided comments about what matters to patients, the perception of the FDA approval process, and what is considered "clinically meaningful." Furthermore, he gave perspective on ways to improve drug development and emphasized the need for policy decisions to be based on scientific evidence and not by sensationalized headlines.


Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Ian Kremer. [LISTEN TIME: 35 minutes]

Dementia and Alzheimer Disease

Latest News